Dr. Joseph Purvis, Rejoins Linical Accelovance America, Increasing Organization's Oncology Expertise
STUART, FL. May 7, 2020 -
Linical Accelovance America (LAA), a market-leading, midsized, global contract research organization (CRO), continues to expand the organization’s medical team with the addition of oncology expert, Dr. Joseph Purvis. Dr. Purvis re-joins LAA as Medical Director and Medical Monitor where he will provide scientific leadership to ensure successful clinical development of clients’ products and their ultimate approval.
“Dr. Purvis is an industry veteran with a background in both large and small CRO’s as well as pharma,” stated Dr. Harish Dave, Global Oncology Therapeutic Head at LAA. “He brings broad experience that will greatly strengthen our medical monitoring and drug development offering. His oncology expertise will further enhance LAA’s established fortitude in this arena. I am delighted to welcome Joe to the team as we grow our capabilities at LAA.”
Dr. Purvis has more than 30 years of Phase I-IV clinical research experience in medical oncology and hematology. He is a knowledgeable and successful pharmaceutical physician, offering extensive experience in developing and registering numerous anticancer compounds. His development experience encompasses a wide variety of compounds, including cytotoxics, hormonal agents, biological agents, and targeted small molecules. Dr. Purvis has a strong background in strategic planning and execution of all phases of clinical development for both US and global regulatory approval. Throughout his career, he has worked closely with regulatory agencies, including the Food and Drug Association (FDA), and European Medicines Agency (EMA), and he has led the management of safety and labeling issues that occur during product development and marketing. In addition to his regulatory background, Dr. Purvis served as a senior Oncologist and Global TA Head for one of the world’s largest CRO.
During his career, Dr. Purvis has played a significant role in the development, approval, and postmarketing of multiple cytotoxic, biological, targeted, and hormonal products; including IV Alkeran®, IV Zyloprim®, Navelbine®, Eloxatin®, Nolvadex®, Faslodex®, Arimidex®, Casodex®, Iressa®, and Torisel®. Dr. Purvis received a BA in Physics from Haverford College and an MD from Jefferson Medical College in Philadelphia, PA. He completed his Internship and Residency at Hartford Hospital, Harford, CT and his Fellowship in Medical Oncology at the Mayo Clinic in Rochester, MN.
Linical is a market-leading, public, midsized CRO with an innovative, hands-on approach to advancing clinical research. Linical is a global, full-service drug development partner, with a significant footprint across North America, Europe, and Asia-Pacific including unique access to the Japanese market. Our areas of expertise include Phase I-IV oncology, vaccine, infectious disease, CNS and general medicine trials, spanning early development compounds to large-scale, multinational studies.